vimarsana.com
Home
Live Updates
Who Should—and Can—Get Lecanemab, the New Alzheimer Disease Drug? | Dementia and Cognitive Impairment | JAMA : vimarsana.com
Who Should—and Can—Get Lecanemab, the New Alzheimer Disease Drug? | Dementia and Cognitive Impairment | JAMA : vimarsana.com
Who Should—and Can—Get Lecanemab, the New Alzheimer Disease Drug? | Dementia and Cognitive Impairment | JAMA
This Medical News story examines the complexity of determining who to treat with lecanemab, the new Alzheimer disease drug.
Related Keywords
United Kingdom ,
Ohio ,
United States ,
New York ,
Kansas ,
Minnesota ,
George Perry ,
Donna Wilcock ,
Eli Lilly ,
Russell Swerdlow ,
James Burke ,
Sam Grandy ,
Madhav Thambisetty ,
Alzeca Bioscience ,
Robert Howard ,
Libby Holman ,
Ivan Cheung ,
Xavier Becerra ,
David Knopman ,
Allison Parks ,
Bioenergetically Active Esters For Health ,
Recuerdo Pharmaceuticals ,
Cure Alzheimer Fund ,
Alzheimer Network For Treatment ,
Us Department Of Health ,
York Stem Cell Foundation ,
University Of Texas At San Antonio ,
Translational Neuroscience Section Laboratory Of Behavioral ,
Centers For Medicare Medicaid Services ,
National Institutes Of Health ,
Brightfocus Foundation ,
Mcknight Brain Research Foundation ,
Indiana University ,
Indiana University School Of Medicine ,
National Institute On Aging ,
Pfizer ,
Drug Administration ,
Lilly Pharmaceuticals ,
University Of Kansas Alzheimer Disease Research Center ,
Astrazeneca ,
Nestle Health Science ,
Journal Of The Alzheimer Association ,
University College London ,
Human Services ,
Alzheimer Network Treatment Unit ,
University Of Southern California ,
Alzheimer Association ,
Johnson ,
Kansas Alzheimer Disease Research ,
San Antonio ,
Might Benefit ,
Who Might ,
New England Journal ,
Indiana University School ,
Ohio State ,
Medicaid Services ,
Monoclonal Antibodies Directed Against Amyloid ,
Disease Registry ,
Alzheimer Network ,
Chiquita Brooks Lasure ,
National Institutes ,
National Institute ,
Translational Neuroscience Section Laboratory ,
Mount Sinai ,
Mayo Clinic Study ,
Interest Disclosures ,
Cognito Therapeutics ,
Third Bridge ,
Vigil Neurosciences ,
Cure Alzheimer ,
New York Stem Cell Foundation ,
Southern California ,
Samus Therapeutics ,
Active Esters ,
Nestle Health ,
Central Nervous System ,
Psychopharmacologic Drugs ,